Gilead Sciences cancer drug hit with partial hold due to adverse event concern
Medcity News,
Five clinical trials testing a Gilead Sciences cancer drug that was the heart of a $4.9 billion acquisition are now paused by…
Five clinical trials testing a Gilead Sciences cancer drug that was the heart of a $4.9 billion acquisition are now paused by…
The first wave of cancer drugs that clear the way for a certain immune cell to gobble up tumors has yet to reach the market…